We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+66.84%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$807M
Cap. Flow
+$35.6M
Cap. Flow %
1.56%
Top 10 Hldgs %
52.32%
Holding
69
New
7
Increased
11
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$37.5M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$36.1M
3
AMRN
Amarin Corp
AMRN
+$32.7M
4
RNAM
Avidity Biosciences
RNAM
+$32.3M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.8M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$65.9M
2
IMMU
Immunomedics Inc
IMMU
+$53.9M
3
RCUS icon
Arcus Biosciences
RCUS
+$27M
4
SAGE
Sage Therapeutics
SAGE
+$15.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$8.82M

Sector Composition

Rank Sector Weight
1 Healthcare 85.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$234M 10.29%
6,606,000
-1,844,000
-22% -$53.9M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$202M 8.86%
1,765,560
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$174M 7.66%
925,000
– –
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$142M 6.26%
3,363,377
– –
RVMD icon
5
Revolution Medicines
RVMD
$39.9B
$93.4M 4.11%
2,959,264
-90,500
-3% -$2.85M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$87.2M 3.83%
2,075,905
– –
BDTX icon
7
Black Diamond Therapeutics
BDTX
$96.8M
$84.9M 3.73%
2,014,858
– –
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$68M 2.99%
400,000
– –
PASG icon
9
Passage Bio
PASG
$14.4M
$52.7M 2.32%
96,416
+2,250
+2% +$1.01M
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$51.6M 2.27%
2,084,883
-1,000,000
-32% -$27M
ESPR
11
DELISTED
Esperion Therapeutics
ESPR
$50M 2.2%
975,000
– –
ALLK
12
DELISTED
Allakos
ALLK
$48.5M 2.13%
675,000
– –
AMRN
13
Amarin Corp
AMRN
$299M
$48.4M 2.13%
350,000
+237,500
+211% +$32.7M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$45.5M 2%
1,094,000
-438,510
-29% -$15.9M
ARGX icon
15
argenx
ARGX
$53.4B
$38.5M 1.69%
170,926
-29,074
-15% -$5.16M
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$36.9M 1.62%
1,733,583
– –
PRNB
17
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$36.3M 1.6%
+607,000
New +$37.5M
CGEN icon
18
Compugen
CGEN
$222M
$35.8M 1.57%
2,383,673
– –
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$35.1M 1.54%
2,325,000
– –
QURE icon
20
uniQure
QURE
$3.03B
$34.5M 1.52%
765,400
– –
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.69B
$33.9M 1.49%
2,287,782
+1,562,000
+215% +$23.8M
GOSS icon
22
Gossamer Bio
GOSS
$82.9M
$33.3M 1.46%
2,562,358
+377,358
+17% +$4.75M
TRIL
23
DELISTED
Trillium Therapeutics Inc.
TRIL
$33M 1.45%
4,075,000
– –
KDMN
24
DELISTED
Kadmon Holdings, Inc.
KDMN
$31.8M 1.4%
6,205,882
– –
RNAM
25
DELISTED
Avidity Biosciences
RNAM
$31.7M 1.39%
+1,121,327
New +$32.3M
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Boxer Capital held 69 positions worth $2.27B, up 55% from $1.47B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital's Q2 2020 filing shows 7 new, 11 increased, 6 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M. The largest sale was Regeneron Pharmaceuticals, an estimated $65.9M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

  • Boxer Capital's largest Q2 2020 buy was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q2 2020, an estimated $36.1M increase.
  • Boxer Capital's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $53.9M.
  • Boxer Capital fully exited Regeneron Pharmaceuticals in Q2 2020, selling an estimated $65.9M.
  • Boxer Capital's ten largest holdings make up 52% of its $2.27B portfolio in Q2 2020.
  • Boxer Capital opened 7 new positions and closed 4 in Q2 2020.
  • Boxer Capital's portfolio value rose 55% quarter-over-quarter to $2.27B.

Based on Boxer Capital's 13F filing for Q2 2020, filed 14 Aug 2020.